William D. J. Roberts, MBA, MSc is a Commonwealth Fund Harkness Fellow and a Research Fellow at both the Harvard T.H. Chan School of Public Health and Brown ...
CMMI has spent more than a decade learning which organizations consistently deliver high-value care. The next step is to let beneficiaries act on that information and allow competition, rather than ...
The surge in vaccine litigation is not simply a post-pandemic, temporary issue. It is a deeper erosion of the legal principles that have long supported public health authority.
CMS and states should look beyond simply expanding disclosure and improving standardization to also elevate antitrust safeguards.
Opinion
When Falls Are Regulated But Function Is Not: How Measurement Incentives Undermine Post-Acute Care
In postacute care, we have built a quality architecture that treats falls as actionable events and functional decline as expected aging. The resulting safety-without-recovery trade-off is not a ...
The emergence of Lilly’s bundling strategy for Zepbound and Taltz reflects the unregulated state of patient assistance programs in the commercial market and the need for Congressional intervention.
While this litigation is unlikely to be resolved in the near term, such lawsuits can be powerful tools in exposing anti-competitive behavior and encouraging transparency and competition in ways that ...
Isaac Kabrick is a fellow with the Center for Health Policy and the Law at the O’Neill Institute. The son of two nurses, Kabrick is interested in connecting peopl ...
As with so many core functions of public health, the future success of vaccine promotion research depends on the support of every institution: government, universities, and industry alike.
Matt Motta, PhD, is an associate professor at the Boston University School of Public Health’s Department of Health Law, Policy, and Management.
Burnout and decreased well-being among primary care physicians threaten workforce sustainability and health outcomes. Understanding how primary care physician burnout and its mitigators differ across ...
Inhaled corticosteroid–long-acting beta-agonist (ICS-LABA) inhalers are widely prescribed for asthma and chronic obstructive pulmonary disease. ICS-LABAs are largely interchangeable within the class; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results